Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Small Molecules Studied

HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10246-1 CPT-11
Irinotecan
LSM-2167 60838
10252-1 Gemcitabine
Gemzar
LSM-5333 60750
10278-1 Topotecan
Hycamtin
LSM-5662 60700
10133-2 Afatinib
BIBW-2992
LSM-43226 57519523
10263-1 LBH589
Panobinostat
LSM-4284 57519507
10345-3 Torkinib
PP242
LSM-6357 57347681
10240-1 AS-252424 LSM-4263 56965900
10219-2 U-0126 LSM-42806 5637
10021-5 Tozasertib
VX680; MK-0457
LSM-1021 5494449
10275-1 (Z)-4-Hydroxytamoxifen LSM-43294 53770298
10518-1 Sulindac sulfide 5352624
10235-2 Everolimus
RAD001
LSM-4258 53398658
10189-2 Bosutinib
SKI-606
LSM-1190 5328940
10281-1 Vinorelbine
Navelbine
LSM-6302 5311497
10282-1 Vorinostat
suberoylanilide hydroxamic acid (SAHA); Zolinza
LSM-3828 5311
10269-1 Oxaliplatin
Eloxatin
LSM-44941 5310940
10023-3 Imatinib
Gleevec; Glivec; CGP-57148B; STI-571
LSM-1023 5291
10343-1 Baicalein LSM-6355 5281605
10242-1 Carboplatin LSM-44959 5237030
10515-1 QNZ
EVP4593
509554
10052-3 Sirolimus
Rapamycin
LSM-1052 5040
10029-2 GW-5074 LSM-1029 5034
10243-1 CGC-11047
PG11047
LSM-4266 476863
10271-2 PD 98059 LSM-3394 4713
10062-3 GSK1070916
KIN001-216
LSM-1062 46885626